China Meheco(SH:600056) Xin Lang Cai Jing·2025-09-18 05:37Core Viewpoint - China Pharmaceutical (SH600056) reached its daily limit up on September 18, 2025, with a closing price of 12.05 yuan, marking a 10.05% increase and a total market capitalization of 18.025 billion yuan [1] Group 1: Company Developments - The company is undergoing strategic adjustments and governance structure optimization, revising multiple rules and simplifying the supervisory board, which is expected to enhance decision-making efficiency and improve governance standards [2] - Several subsidiaries have obtained European CEP certification and multiple approvals for active pharmaceutical ingredients, leading to a 50% increase in international business revenue, indicating significant progress in international expansion [2] - The company has enriched its R&D pipeline with multiple subsidiaries' drugs passing consistency evaluations or obtaining registration certificates, which is likely to help gain more market share [2] - The company announced a cash dividend of 0.1966 yuan per 10 shares, reflecting a healthy cash flow situation, and has established a systematic market value management framework, promising to increase the frequency and proportion of cash dividends [2] Group 2: Industry Context - The pharmaceutical sector has seen some stocks become active recently due to international business expansion and R&D advancements, with capital inflow noted in the sector on September 18 [2] - Technical indicators suggest that if the MACD forms a golden cross and the stock price breaks through key resistance levels, it may attract more technical investors [2] - Monitoring data indicates a favorable net buying situation from large orders on that day, suggesting that major funds are optimistic about the company's growth prospects [2]